Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.
作者： P. Schirmacher , B. Sangro , C. Verslype , I. Chau , J. Ricke
DOI: 10.1016/J.ANNONC.2021.02.014
关键词:
摘要: … b ESMO-MCBS v1.1 score for new therapy/indication approved by the EMA since January 1, 2016. The score has been … Table 8ESMO-MCBS table for new therapies/indications in HCC …
annalsofoncology.org
sci-hub.st 参考文章(13)
Lorenza Rimassa, Armando Santoro, Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial Expert Review of Anticancer Therapy. ,vol. 9, pp. 739- 745 ,(2009) , 10.1586/ERA.09.41
V. Di Marco, F. De Vita, J. Koskinas, D. Semela, P. Toniutto, C. Verslype, Sorafenib: from literature to clinical practice Annals of Oncology. ,vol. 24, pp. 30- 37 ,(2013) , 10.1093/ANNONC/MDT055
B Escudier, V Kataja, None, Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of Oncology. ,vol. 27, pp. 706- 720 ,(2010) , 10.1093/ANNONC/MDU259
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder, René Gerolami, Gianluca Masi, Paul J Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Masatoshi Kudo, Ann-Lii Cheng, Josep M Llovet, Richard S Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han, None, Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet. ,vol. 389, pp. 56- 66 ,(2017) , 10.1016/S0140-6736(16)32453-9
N.I. Cherny, U. Dafni, J. Bogaerts, N.J. Latino, G. Pentheroudakis, J.-Y. Douillard, J. Tabernero, C. Zielinski, M.J. Piccart, E.G.E. de Vries, ESMO-Magnitude of Clinical Benefit Scale version 1.1 Annals of Oncology. ,vol. 28, pp. 2340- 2366 ,(2017) , 10.1093/ANNONC/MDX310
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem, Jean Frederic Blanc, Arndt Vogel, Dmitry Komov, T R Jeffry Evans, Carlos Lopez, Corina Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, Ann-Lii Cheng, Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial The Lancet. ,vol. 391, pp. 1163- 1173 ,(2018) , 10.1016/S0140-6736(18)30207-1
Ghassan K. Abou-Alfa, Tim Meyer, Ann-Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa, Baek-Yeol Ryoo, Irfan Cicin, Philippe Merle, YenHsun Chen, Joong-Won Park, Jean-Frederic Blanc, Luigi Bolondi, Heinz-Josef Klümpen, Stephen L. Chan, Vittorina Zagonel, Tiziana Pressiani, Min-Hee Ryu, Alan P. Venook, Colin Hessel, Anne E. Borgman-Hagey, Gisela Schwab, Robin K. Kelley, Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma The New England Journal of Medicine. ,vol. 379, pp. 54- 63 ,(2018) , 10.1056/NEJMOA1717002
Ho Yeong Lim, Kun-Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean-Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo B Abada, Masatoshi Kudo, Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S Finn, Peter R Galle, Josep M Llovet, Eric Assenat, Giovanni Brandi, Marc Pracht, Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology. ,vol. 20, pp. 282- 296 ,(2019) , 10.1016/S1470-2045(18)30937-9
T. Yau, J.W. Park, R.S. Finn, A.-L. Cheng, P. Mathurin, J. Edeline, M. Kudo, K.-H. Han, J.J. Harding, P. Merle, O. Rosmorduc, L. Wyrwicz, E. Schott, S.P. Choo, R.K. Kelley, D. Begic, G. Chen, J. Neely, J. Anderson, B. Sangro, CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) Annals of Oncology. ,vol. 30, ,(2019) , 10.1093/ANNONC/MDZ394.029
Richard S. Finn, Baek-Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, Valeriy Breder, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer Knox, Bruno Daniele, Scot W. Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann-Lii Cheng, , Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Journal of Clinical Oncology. ,vol. 38, pp. 193- 202 ,(2020) , 10.1200/JCO.19.01307